key: cord-0797842-azoiv96e
authors: Guan, Jin-Tao; Wang, Wei-Jie; Lei, Shan-Shan; Xu, Zheng-Hao
title: Author response to: correspondence to: ‘A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients’
date: 2021-11-21
journal: Ther Adv Chronic Dis
DOI: 10.1177/20406223211055922
sha: f5bad85215f1800865ff16fe14416fb878447ca8
doc_id: 797842
cord_uid: azoiv96e

nan

We read the letter from Pankaj et al., which is regarding our recent study titled 'A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients'. 1 We appreciate their attention and agree with them that we have mistakenly included several studies evaluating the role of IL-6 inhibitors. We have also noticed this error by a kindly email from Dr. Stefan Steidl, Vice President, Disease Biology & Translational Research, on 27 August 2021.

Immediately after reading the email from Dr. Stefan Steidl, I (Z.X.) discussed with the two co-first authors (J.G. and W.W.) and another corresponding author (S.L.). Considering this topic is very interesting and important, as well as that unpredictable outcomes may be resulted from these errors, all the authors reach a consensus on trying to do a correction or update analysis. Thus, we did an updated systematic literature search from 1 December 2019 to 29 August 2021, which was limited to anti-GM-CSF therapy. Finally, we collected six studies, including the two previous cohort studies 2,3 and four new randomized controlled trials. 4-7 Based on these new pieces of evidence, we have finished the update meta-analysis and have emailed it to the editorial office to apply a formal correction.

In our update meta-analysis, a total of six eligible literature involving 1542 COVID-19 patients were recruited, including anti-GM-CSF therapy treatment group (n = 761) and control group (n = 781). Using a random-effect model, we Thank you very much!

A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-cohort study

A randomized trial of otilimab in severe COVID-19 pneumonia (OSCAR)

Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial

Lenzilumab efficacy and safety in newly hospitalized Covid-19 subjects: results from the live-air phase 3 randomized doubleblind placebo-controlled trial